Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, 464-8681, Japan.
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
Future Oncol. 2021 Mar;17(8):869-875. doi: 10.2217/fon-2020-0621. Epub 2020 Sep 21.
Nivolumab is an increasingly used standard care treatment for heavily pretreated patients with advanced gastric cancer, with increasing clinical use in Japan. Data from retrospective studies on various tumors have shown the objective response rate to cytotoxic chemotherapy potentially improves after an exposure to immune checkpoint inhibitors. Based on these data, we conducted the multicenter observational REVIVE study to evaluate the efficacy and safety of cytotoxic chemotherapy in nivolumab-refractory or nivolumab-intolerant patients with advanced gastric cancer. Patients who are refractory or intolerant to nivolumab and scheduled to receive irinotecan monotherapy, oxaliplatin combination treatment or oral trifluridine/tipiracil hydrochloride therapy will be included. The primary end point is overall survival of nivolumab-pretreated patients with advanced gastric cancer after the cytotoxic chemotherapy. UMIN000032182 (umin.ac.jp).
纳武利尤单抗是一种广泛应用于晚期胃癌的标准治疗药物，在日本的临床应用也在不断增加。来自各种肿瘤的回顾性研究数据表明，在接受免疫检查点抑制剂治疗后，细胞毒性化疗的客观缓解率可能会提高。基于这些数据，我们开展了多中心观察性 REVIVE 研究，以评估细胞毒性化疗在纳武利尤单抗难治或不耐受的晚期胃癌患者中的疗效和安全性。将纳入对纳武利尤单抗耐药或不耐受且计划接受伊立替康单药、奥沙利铂联合治疗或口服氟嘧啶替匹嘧啶治疗的患者。主要终点是纳武利尤单抗预处理的晚期胃癌患者接受细胞毒性化疗后的总生存期。UMIN000032182（umin.ac.jp）。
Zotero 插件